title: Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
abstract: This study was performed to assess whether patients with Parkinson's disease (PD)develop cognitive and psychiatric impairments more frequently during therapy with continuous subcutaneous apomorphine infusion (CAI) compared to the standard oral treatment. Thirty consecutive PD patients with severe motor fluctuations were included. Of them, 12 patients received the CAI treatment, while the remaining 18 continued the treatment with oral dopaminergic drugs. The two groups were evaluated with neuropsychological,psychiatric and motor tests at baseline and after two years. The off-awake daily duration and the levodopa dosage were significantly reduced in the patients infused with apomorphine.In comparison with the baseline evaluation, the neuropsychiatric assessment did not change in either of groups at the follow-up, except for a significant improvement of mood in the CAI treated group.
authors.affiliation: Department of Neuroscience, Psychiatry and Anesthesiology,I-98125 Messina, Italy. morgante@unime.it
authors.forename: L
authors.initials: L
authors.lastname: Morgante
authors.forename: G
authors.initials: G
authors.lastname: Basile
authors.forename: A
authors.initials: A
authors.lastname: Epifanio
authors.forename: E
authors.initials: E
authors.lastname: Spina
authors.forename: A
authors.initials: A
authors.lastname: Antonini
authors.forename: F
authors.initials: F
authors.lastname: Stocchi
authors.forename: E
authors.initials: E
authors.lastname: Di Rosa
authors.forename: G
authors.initials: G
authors.lastname: Martino
authors.forename: R
authors.initials: R
authors.lastname: Marconi
authors.forename: P
authors.initials: P
authors.lastname: La Spina
authors.forename: V
authors.initials: V
authors.lastname: Nicita-Mauro
authors.forename: A E
authors.initials: AE
authors.lastname: Di Rosa
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use; D001058:Apomorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology; D003072:Cognition Disorders / Q000150:complications* / Q000175:diagnosis; D003863:Depression / Q000150:complications* / Q000175:diagnosis / Q000523:psychology*; D004294:Domperidone / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D012720:Severity of Illness Index; D016037:Single-Blind Method; D011795:Surveys and Questionnaires
chemical_list: D000932:Antiemetics; D018491:Dopamine Agonists; D004294:Domperidone; D001058:Apomorphine